Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. - Wikidata - awgldk - TriplyDB

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

http://www.wikidata.org/entity/Q34561518

about

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation PLK1, A Potential Target for Cancer Therapy Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.Cell cycle proteins as promising targets in cancer therapy The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.

P2860

Q26784048-62A32950-F708-4046-A93F-4798CF8439B0 Q28078772-9780DFBE-9ED5-47B9-88C7-C21123F2A6FE Q35819646-B51B5966-CCD7-495A-8461-768DBD789D32 Q36012586-538A567B-A93C-4AB3-80AA-37106C4FEE5E Q36267151-59878791-9663-4429-9A22-ACF0836226A1 Q36516564-1C4EBEEF-320B-4D4E-AF28-4D8A51102C34 Q36751562-FCC81EFD-C741-490A-9227-B8C63B05DCB1 Q37447866-B7DFC93F-D8B5-43F7-94BC-6B689935339E Q37693690-AE5A4CC6-A874-4118-B54F-A7E5D8C9054C Q37701672-0CFD5DA6-49F8-4E0C-9A84-6BA497412630 Q38824242-ECABBD12-B2ED-44A3-B835-EAD7B76CB2B5 Q38837564-130EBAE0-1069-446A-9CDF-9416FF2B2191 Q38844740-69AEF431-83EB-4F59-925F-603016DC8755 Q39372427-E49F2D01-7F7A-4A40-8D76-6A865CF59D3A Q39954004-9AC3FFB7-D37E-4189-9B6A-76B28871676E Q40309145-F16C96DD-A4D4-4D21-8649-FF5BD191565D Q41592750-EC469D71-D98D-4715-882B-8D9AAC197D0B Q41819580-62C4DB6B-5EAC-4030-A6BA-BB5E881963BE Q47143476-7C2FCF6A-E9E8-41A8-B8E4-BFA160407530 Q48253128-EEA3F472-E98F-4991-B2AA-77AFB1A21483 Q53066951-B7E37B22-483E-4DAA-80EB-577075ED4CD3

P2860

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

http://www.wikidata.org/entity/Q34561518

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@ast

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@en

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@nl

type

label

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@ast

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@en

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@nl

prefLabel

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@ast

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@en

Initial testing (stage 1) of t ...... c Preclinical Testing Program.

@nl

P1433

Q34561518-B312A7B0-5E97-4190-9838-E3F20F00A82C

P1476

Q34561518-731F11DA-84B3-406B-8A01-B9A9DCD2E4F4

P2093

Q34561518-3F800394-4A2C-4354-8E17-547E235151D5

Q34561518-409C7741-42F0-4F6E-AB03-AC16845D847F

Q34561518-76977DEE-FB0F-4A19-B1C0-D492F495C368

Q34561518-B249EBB0-5C12-48E5-8EAF-C87E9F8E9B89

Q34561518-C28CA691-10C3-4D0B-A60F-E915650BCF3C

Q34561518-DC1D2804-6E10-4C37-BE37-48FAA692ECA9

Q34561518-EB7F8367-0ED7-46CE-9EB1-6064982EA42B

P2860

Q34561518-00DD8FD0-8691-4443-AEED-3FF1975124B8

Q34561518-09528C26-FA8F-4435-B193-30DA479BF9C1

Q34561518-18A47506-61FB-46B4-8079-34161DA9727C

Q34561518-1F73C40E-9792-442B-8BB4-A8DE87741745

Q34561518-2AF81CE0-C493-4AD4-8C3F-1143D600AE65

Q34561518-2B8F2CBB-4654-4D73-B4F0-E37856D9047A

Q34561518-3F98F67F-BA20-4630-9423-0414160BC813

Q34561518-40FA248A-7584-45FC-9709-EAD9362877A4

Q34561518-4ED591F2-212D-40C2-963D-7011B5EEEB45

Q34561518-74E15DB2-2A98-4FB4-B121-69694E837B0C

P304

Q34561518-69273447-CBDE-47CD-A18B-3E8C008588DC

P31

Q34561518-4072DA57-0670-4142-89D5-297B46921CE3

P356

Q34561518-CD1715D1-63F6-447C-9C70-C517C0E48BC3

P433

Q34561518-CB91AE27-73FE-407C-85DC-4E83D6C1C04D

P478

Q34561518-13E42E8F-47C7-45BF-A999-5BBED8A2A457

P50

Q34561518-283F1BCA-AA43-45AC-B327-7B34C556743B

Q34561518-64C25201-F809-49DE-A289-6346FBE0A3A2

Q34561518-8D1FE9F6-D724-4F9B-827B-A7088DE96B99

Q34561518-9C94EA08-0E47-4D65-9085-8307EF7890B6

Q34561518-C957AFD3-819C-4F79-8F0F-FC1C76EC00B3

P577

Q34561518-AEA01F5A-7552-47CF-BE51-BBA14F643546

P5875

Q34561518-FF63D1AE-2815-443D-88E7-9A02D58820C9

P698

Q34561518-559EC066-1C70-40CE-BD00-3F1F72FB9AE9

P932

Q34561518-B8EEC913-4248-45AA-9934-2A46D48193E9

P356

P1433

Pediatric Blood & Cancer

P1476

Initial testing (stage 1) of t ...... ic Preclinical Testing Program

@en

P2093

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Raushan T Kurmasheva

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

P2860

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Initial testing of topotecan by the pediatric preclinical testing program.

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.

P304

158-164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24616

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

Malcolm A Smith

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255976570

http://www.w3.org/2001/XMLSchema#string

P698

23956067

http://www.w3.org/2001/XMLSchema#string

P932

4241497

http://www.w3.org/2001/XMLSchema#string